Publicacions en què col·labora amb Maria Eugenia De La Morena Barrio (10)

2018

  1. Biochemical and cellular consequences of the antithrombin p.Met1? Mutation identified in a severe thrombophilic family

    Oncotarget, Vol. 9, Núm. 69, pp. 33202-33214

2017

  1. High levels of latent antithrombin in plasma from patients with antithrombin deficiency

    Thrombosis and Haemostasis, Vol. 117, Núm. 5, pp. 880-888

2016

  1. Antithrombin Dublin (p.Val30Glu): A relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency

    Thrombosis and Haemostasis, Vol. 116, Núm. 1, pp. 146-154

2015

  1. A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event

    Thrombosis Research, Vol. 136, Núm. 3, pp. 634-641

2014

  1. Role of the C-sheet in the maturation of N-glycans on antithrombin: Functional relevance of pleiotropic mutations

    Journal of Thrombosis and Haemostasis, Vol. 12, Núm. 7, pp. 1131-1140

2013

  1. Identification of Antithrombin-Modulating Genes. Role of LARGE, a Gene Encoding a Bifunctional Glycosyltransferase, in the Secretion of Proteins?

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism

    Blood, Vol. 120, Núm. 4, pp. 900-904

  2. Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency

    Thrombosis and Haemostasis, Vol. 107, Núm. 3, pp. 430-437

  3. The infective polymerization of conformationally unstable antithrombin mutants may play a role in the clinical severity of antithrombin deficiency.

    Molecular medicine (Cambridge, Mass.), Vol. 18, pp. 762-770

2011

  1. Heparin affinity of factor VIIa: Implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa

    Thrombosis Research, Vol. 127, Núm. 2, pp. 154-160